Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases.
Berenson JR, Rosen LS, Howell A, Porter L, Coleman RE, Morley W, Dreicer R, Kuross SA, Lipton A, Seaman JJ.
Berenson JR, et al. Among authors: coleman re.
Cancer. 2001 Apr 1;91(7):1191-200. doi: 10.1002/1097-0142(20010401)91:7<1191::aid-cncr1119>3.0.co;2-0.
Cancer. 2001.
PMID: 11283917
Clinical Trial.